Citadel Advisors’s NEOPHOTONICS CORP NPTN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-36,100
Closed -$314K 15317
2021
Q3
$314K Buy
+36,100
New +$329K ﹤0.01% 10979
2021
Q1
Sell
-10,700
Closed -$97K 13941
2020
Q4
$97K Buy
+10,700
New +$82.8K ﹤0.01% 10244
2020
Q2
Sell
-18,700
Closed -$136K 10759
2020
Q1
$136K Buy
18,700
+3,200
+21% +$23.7K ﹤0.01% 8384
2019
Q4
$137K Buy
+15,500
New +$116K ﹤0.01% 8412
2019
Q3
Sell
-32,800
Closed -$137K 9975
2019
Q2
$137K Sell
32,800
-14,900
-31% -$78.6K ﹤0.01% 8402
2019
Q1
$300K Buy
47,700
+24,900
+109% +$174K ﹤0.01% 7613
2018
Q4
$148K Sell
22,800
-23,500
-51% -$180K ﹤0.01% 8066
2018
Q3
$384K Buy
46,300
+18,300
+65% +$139K ﹤0.01% 7151
2018
Q2
$174K Sell
28,000
-96,800
-78% -$616K ﹤0.01% 7991
2018
Q1
$855K Sell
124,800
-50,000
-29% -$318K ﹤0.01% 5041
2017
Q4
$1.15M Buy
174,800
+137,300
+366% +$839K ﹤0.01% 4459
2017
Q3
$209K Buy
37,500
+26,500
+241% +$179K ﹤0.01% 6635
2017
Q2
$85K Sell
11,000
-700
-6% -$5.92K ﹤0.01% 6964
2017
Q1
$105K Buy
+11,700
New +$122K ﹤0.01% 6844
2016
Q4
Sell
-14,300
Closed -$234K 8053
2016
Q3
$234K Buy
+14,300
New +$201K ﹤0.01% 6084
2016
Q2
Sell
-29,900
Closed -$420K 7591
2016
Q1
$420K Buy
29,900
+26,200
+708% +$271K ﹤0.01% 4644
2015
Q4
$40K Buy
3,700
+2,500
+208% +$22.6K ﹤0.01% 7483
2015
Q3
$8K Sell
1,200
-6,200
-84% -$48K ﹤0.01% 8543
2015
Q2
$68K Buy
+7,400
New +$56.1K ﹤0.01% 7437

Other funds holding NPTN

Citadel Advisors's NPTN Position: Q3 2022 in Review

Citadel Advisors sold out of NEOPHOTONICS CORP (NPTN) in Q3 2022, closing a stake of 260,595 shares — an estimated $4.1M sold.

Citadel Advisors first reported a position in NPTN in Q2 2014 and held it in 29 quarters. The position peaked at $6.88M in Q1 2016. 2 funds tracked by Wall St. Rank hold NPTN as of Q3 2022.

  • Citadel Advisors reported no remaining NEOPHOTONICS CORP position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 260,595 NEOPHOTONICS CORP shares in Q3 2022, an estimated $4.1M.
  • Citadel Advisors first reported a position in NEOPHOTONICS CORP in Q2 2014 and held it in 29 quarters.
  • Citadel Advisors's NEOPHOTONICS CORP position peaked at $6.88M in Q1 2016.
  • 2 funds tracked by Wall St. Rank held NEOPHOTONICS CORP as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.